Figures & data
Figure 1. CT scan image of brain tumor.
Figure 2. Diagrammatic representation of functionalization of biologically synthesized gold nanoparticles for the attachment of monoclonal antibody and anticancer drug.
Figure 3. Representation of passive targeting of drug. Nanoparticles accumulated in tumor because blood brain barrier selectively disrupted at the site of malignant lesion.
Figure 4. Representation of active targeting of drug. Use of antibody-nanoparticles conjugates can target tumor cells only and deliver the drug at specific site (tumor cell).
Figure 5. Diagrammatic representation of receptor-mediated endocytosis to cross the BBB and deliver the drug at targeted site only. (A) Representation of BBB, (B) Intravenously injection of nanocarrier, (C) Transferrin attached to BBB receptor. (D, E & F) Receptor mediated endocytosis of nanocarrier and reached into brain by exocytosis, (G) Finally, nanocarrier attached with tumor cells only through monoclonal antibody.
